




Collagen Solutions Plc

Jamal Rushdy, CEO

Gill Black, CFO

June, 2016



Disclaimer

This presentation is incomplete without reference to, and should be viewed solely in conjunction with the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. This presentation has not been examined, reviewed or compiled by the Company's independent certified accountants.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company's control or with in the Company's control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

By attending the presentation, or reading or accepting this document you agree to be bound by the foregoing limitations.



Company Overview

Opportunity

\$1.5b+ biomaterials market opportunity growing 10%+

Focused Business Model

Biomaterials core business + licensing and distribution of owned products

Innovation & I.P.

Broad technology range, novel I.P., unique experience and know-how


Experienced Team

End-user experience in medical devices and biomaterials

Global Customer Base

Customers in multiple markets, geographies, and growth stages

Our Strategy Addresses a Significant Opportunity





Technology, Innovation & I.P., Know-How

Technology

- Medical grade collagen - broad range of solutions, powder, sheets, gels
- Tissues – processed pericardium, bone, tendon, and other materials

Innovation & I.P.

- Issued, pending, and in-process processing technology I.P.
- Acquired ChondroMimetic – several orthopaedic applications

Know-How

- Experienced global team in collagen and biomaterials
- >50% employees with advanced technical degrees
- >85% employees with experience in relevant customer markets

Experienced Management Team In Place



Jamal Rushdy, CEO ¹

- 20+ years medical devices, orthopaedics and biologics
- 8+ years as Vice President, Tornier (NASDAQ:TRNX, acquired)
- 4+ years DJO (NYSE:DJO, acquired by Private Equity)
- 3 start-ups with successful exits
- M&A, marketing, sales ops, finance



Stewart White PhD, CSO ¹

- Founding CEO, Collagen Solutions and Collbio
- International operations, business and product development
- GMP compliant operations for collagen medical devices and active pharmaceutical ingredients



Tom Hyland, COO

- Collagen chemistry expertise
- Six sigma black belt
- Multiple successful collagen-based product introductions



Gill Black, CFO ¹

- Board-level financial experience
- Financial director at A&E Russell through growth and acquisition
- Senior manager KPMG



Geoff Bennett, Executive Director ¹

- Co-founder and CEO of Southern Lights Biomaterials
- CFO at three public Canadian companies



David Evans, Chairman ²


- Proven track record in acquiring, integrating and growing businesses in healthcare
- Successful exits with multiple diagnostic & healthcare companies
- Currently Chairman of OptiBiotix Health Plc and Premaitha Health Plc.



Malcolm Gillies, Non-Executive Director ²

- Director experience in several private and public companies in healthcare
- Former senior partner, corporate finance lawyer, Shepherd+Wedderburn.
- Board-level financial experience

Early Share Gains Driving Revenue Growth




*Year ending 31 March 2016 unaudited pre-announced 3 May 2016.

Global Diverse Customer Base

Customer base demographics

- USA, Canada, Northern Europe, Middle East, and Korea
- Large \$1b+ medical devices
- Medium \$100m-\$500m medical devices
- Multiple early growth stage & pre-revenue




Our Vision

To become the industry's first choice
for regenerative biomaterials



We Offer Foundational Products in the Large Regenerative Biomaterials Sector



Collagen and Tissue Biomaterials Applications

- Multiple markets in medical devices, regenerative medicine, and research
 - Major markets are cardiovascular, orthopaedics, dental, and wounds
- Estimated \$15b+ end-user market; \$1.5b+ addressable supplier market
 - 10%+ growth driven by patient demographics & continued innovation




Cardiovascular
Dental
Ear, Nose Throat
General & gastroenterology surgery
Oncology
Ophthalmic
Orthopaedic
Neurology
Plastic & reconstructive surgery
Preclinical Research
Tissue Engineering
Trauma
Urinary
Wound Repair

Example Products

Cardiovascular	Orthopaedics	Wounds
<ul style="list-style-type: none"> • Heart valves • Vascular closure • Vascular grafts • Stent coatings 	<ul style="list-style-type: none"> • Bone graft substitutes • Demineralised bone matrix • Tendon and ligament repair • Cartilage reconstruction 	<ul style="list-style-type: none"> • Wound sponges • Wound scaffolds • Burn grafts • Dressings

Operating Across the Value Chain Unlocks Value...



...and a Partner & Licensing Model Enables Focus

- Last 40%-60% of end-user price requires significant expertise and expense
- Partner & licensing model leverages COS' sales channel and competencies

Our Core Biomaterials Address Multiple Needs

Medical Grade Collagen

- Tissue Engineering scaffolds
- Medical Device components
- Research assays



Pericardium & Other Tissues

- Natural and semi-processed tissues
- Ideal physical and biologic properties for medical devices
- Examples - heart valves and dental membranes



Our Finished Product Categories Meet Different Customer Segment Demands


Market Access

- **Owned products** or **co-developed to partner specification**
- Demand in orthopaedics, dental, cardiovascular, etc.
- Leverage development across many customers




Premier

- **Owned products** through acquired or developed I.P.
- Selective partners with more exclusive licensing
- Cartilage regeneration as an example

Finished Products



Customer Segmentation Drives Focus and Value


Research & Diagnostics	Medical Devices	Regenerative Medicine
		
<ul style="list-style-type: none">• Use specialised distributors• Off-the-shelf formulations• Upstream brand value	<ul style="list-style-type: none">• Sell to medical device companies & distribution partners• Development, supply, manufacturing, & finished devices• Specialised consultative sales process	

Customer-Driven Value Proposition



Working Together	World Class Standards	Broad Range of Materials
<p>Scientific expertise and a collaborative approach:</p> <ul style="list-style-type: none"> • Faster time to market • Improved production • Superior products 	<p>GMP, EDQM, ISO 13485 & 22442, materials sourced from BSE-free countries:</p> <ul style="list-style-type: none"> • Regulatory approvals • Quality and consistency • Safe, reliable supply 	<p>A comprehensive range of collagen biomaterials and forms:</p> <ul style="list-style-type: none"> • Tissues • Powders • Coatings • Sponges • Membranes • Scaffolds

ChondroMimetic Product Pipeline Opportunity



Acquired assets of former OrthoMimetics Ltd 9/2015


- Cartilage, bone, meniscus, tendon and ligament orthopaedic regenerative platform
- Global orthobiologics market \$3.7b+, reaching \$5.5 billion by 2018.

ChondroMimetic is the primary opportunity

- Previously launched in Europe, 6+ years evidence in patients
- Retro study and CE mark for OUS launch early 2017



Thank You






Appendix: Financials


Gill Black, CFO

Six Months ended 30 September 2015


Revenue & Other Income (£)




Gross Profit (£)




Gross Margin (%)




LBITDA* (£)



EPS (p)



Cash and Equivalents (£)



*Before separately identifiable items – acquisition and integration costs.